Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
AstraZeneca revealed on Tuesday, Dec. 26, that it will buy the China-based biopharmaceutical company Gracell Biotechnologies for up to $1.2 billion. The Anglo-Swedish multinational pharma and biotechnology firm is making this move to achieve its cell therapy ambitions.
According to Reuters, AstraZeneca is also aiming to use the acquisition of Gracell Biotechnologies to boost its presence in China, which is currently the second-largest pharmaceutical market in the world, further.
Payment Terms and Other Acquisition Arrangements
AstraZeneca and Gracell agreed to an all-cash deal for the acquisition. Once the buyout is completed, the former’s portfolio is set to expand with the addition of several experimental therapies.
AstraZeneca is buying the Chinese firm at $2 per ordinary share. This is also equivalent to $10 per American Depository Share of Gracell, which represents a premium of 61.6% based on its Dec. 22 closing.
Merging of Expertise to Achieve Growth and New Biotech Innovation
AstraZeneca and Gracell are looking to combine their respective expertise and resources to develop effective therapies for diseases. They also expect to find new ways of optimizing the therapeutic profile of engineered T cells and take the lead in the next generation of autologous cell therapies.
“The proposed acquisition of Gracell will complement AstraZeneca’s existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies (TCR-Ts) in solid tumors,” AstraZeneca’s executive vice president of Oncology research and development, Susan Galbraith, said in a press release.
She further explained, “GC012F will accelerate our cell therapy strategy in hematology with the opportunity to bring a potential best-in-class treatment to patients living with blood cancers using a differentiated manufacturing process, as well as exploring the potential for cell therapy to reset the immune response in autoimmune diseases.”
Gracell Biotechnologies’ founder, chairman, and chief executive officer, Dr. William Cao, also commented, “We look forward to working with AstraZeneca to accelerate our shared goal of bringing transformative cell therapies to more patients living with debilitating diseases.”
Photo by: Declan Sun/Unsplash
